Radioimmunotherapeutic approaches for leukemia: the past, present and future
β Scribed by Pagel, J.M.
- Book ID
- 122329505
- Publisher
- Informa plc
- Year
- 2008
- Tongue
- English
- Weight
- 153 KB
- Volume
- 10
- Category
- Article
- ISSN
- 1465-3249
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The development of BcrβAbl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standardβdose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, pr
There have been a number of major advances made in the field of bioactive ceramics, glasses and glass ceramics during the past 30-40 years. From initial work on the development of materials that are tolerated in the physiological environment, emphasis has now shifted towards the use of ceramic mater